We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » InterMune Halts Phase III Trial Due to Shorter Survival Times
InterMune Halts Phase III Trial Due to Shorter Survival Times
February 22, 2006
Unfavorable outcomes prompted the California biotech firm InterMune to halt its Phase III trial of Actimmune (interferon gamma-1b), a chemotherapy adjunct, the company announced Feb. 2.